NCT03174587View on ClinicalTrials.gov

Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

March 12, 2019

Study Completion Date

August 19, 2019

Conditions
Lupus Nephritis
Interventions
BIOLOGICAL

allogenic bone marrow derived mesenchymal stem cells

Step -1 dose : 1.0x10\^6cells/kg Step 1 dose : 2.0x10\^6cells/kg Step 2 dose : 3.0x10\^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days

Trial Locations (1)

04763

Hanyang university hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Hanyang University

OTHER

lead

Corestemchemon, Inc.

INDUSTRY

NCT03174587 - Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis | Biotech Hunter | Biotech Hunter